Vaccination Against Hepatitis B Virus in Cirrhotic Patients on Liver Transplant Waiting List
Patients with cirrhosis may fail to respond to anti–hepatitis B vaccine. An adequate response would be especially interesting when patients are on a liver transplant waiting list. Posttransplantation de novo hepatitis B has been well documented. One possible source is the grafting of organs from hep...
Gespeichert in:
| Veröffentlicht in: | Liver transplantation 2000-07, Vol.6 (4), p.440-442 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 442 |
|---|---|
| container_issue | 4 |
| container_start_page | 440 |
| container_title | Liver transplantation |
| container_volume | 6 |
| creator | Domı́nguez, Mercedes Bárcena, Rafael Garcı́a, Miguel López-Sanroman, Antonio Nuño, Javier |
| description | Patients with cirrhosis may fail to respond to anti–hepatitis B vaccine. An adequate response would be especially interesting when patients are on a liver transplant waiting list. Posttransplantation de novo hepatitis B has been well documented. One possible source is the grafting of organs from hepatitis B surface antigen (HBsAg)–negative, antibody to HBsAg (anti-HBs)–positive, antibody to hepatitis B core antigen–positive donors. The achievement of high titers of anti-HBs could be protective in this setting. We studied prospectively the response rate to recombinant hepatitis B vaccine (3 40-μg doses administered at 0, 1, and 2 months) in 62 patients with end-stage liver disease awaiting liver transplantation. Twenty-two patients showed antibody response (44%). A further 3 doses were administered in 15 of 28 nonresponders and were effective in 9 patients. Thus, the response rate reached 62% (31 of 50 patients completing 1 or 2 vaccination schedules before liver transplantation). Classic hepatitis B vaccination studies of patients with cirrhosis yield lower response rates. Vaccination with this double-dose schedule should be considered in such patients before liver transplantation. (Liver Transpl 2000;6:440-442.) |
| doi_str_mv | 10.1053/jlts.2000.8313 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71278867</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1527646500872238</els_id><sourcerecordid>71278867</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4613-34fc2e15fa9a62a7b94b71acd53c5394c09c4ef77fe68c81b2cb99b434d70a133</originalsourceid><addsrcrecordid>eNqFkU1L7DAUhoMofm9dXrKSu5kxp0madqnD9QMGdDHqRghpeqqRTjsmmRH_vRkr4ubqKiHneV8OTwg5AjYGJvnJcxvDOGOMjQsOfIPsgszUKBeKb37dc7lD9kJ4ZgxAlmyb7AArQUIud8nDnbHWdSa6vqOnj8Z1IdJLXKSH6AI9o3fOLwN1HZ0475_66Cy9SUPsYqApMnUr9HTmTRcWrekivTcp2D2mQYgHZKsxbcDDz3Of3J7_m00uR9Pri6vJ6XRkRQ58xEVjMwTZmNLkmVFVKSoFxtaSW8lLYVlpBTZKNZgXtoAqs1VZVoKLWjEDnO-T46F34fuXJYao5y5YbNNC2C-DVpCposhVAv_-CEImVSE5z4qEjgfU-j4Ej41eeDc3_k0D02v1eq1er9XrtfoU-PPZvazmWH_DB9cJUAPw6lp8-6VOT2cy3XMmPqqLIYlJ4sqh18GmH7BYO4826rp3_9vqHSCUo2E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1257853328</pqid></control><display><type>article</type><title>Vaccination Against Hepatitis B Virus in Cirrhotic Patients on Liver Transplant Waiting List</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Domı́nguez, Mercedes ; Bárcena, Rafael ; Garcı́a, Miguel ; López-Sanroman, Antonio ; Nuño, Javier</creator><creatorcontrib>Domı́nguez, Mercedes ; Bárcena, Rafael ; Garcı́a, Miguel ; López-Sanroman, Antonio ; Nuño, Javier</creatorcontrib><description>Patients with cirrhosis may fail to respond to anti–hepatitis B vaccine. An adequate response would be especially interesting when patients are on a liver transplant waiting list. Posttransplantation de novo hepatitis B has been well documented. One possible source is the grafting of organs from hepatitis B surface antigen (HBsAg)–negative, antibody to HBsAg (anti-HBs)–positive, antibody to hepatitis B core antigen–positive donors. The achievement of high titers of anti-HBs could be protective in this setting. We studied prospectively the response rate to recombinant hepatitis B vaccine (3 40-μg doses administered at 0, 1, and 2 months) in 62 patients with end-stage liver disease awaiting liver transplantation. Twenty-two patients showed antibody response (44%). A further 3 doses were administered in 15 of 28 nonresponders and were effective in 9 patients. Thus, the response rate reached 62% (31 of 50 patients completing 1 or 2 vaccination schedules before liver transplantation). Classic hepatitis B vaccination studies of patients with cirrhosis yield lower response rates. Vaccination with this double-dose schedule should be considered in such patients before liver transplantation. (Liver Transpl 2000;6:440-442.)</description><identifier>ISSN: 1527-6465</identifier><identifier>EISSN: 1527-6473</identifier><identifier>DOI: 10.1053/jlts.2000.8313</identifier><identifier>PMID: 10915165</identifier><language>eng</language><publisher>Philadelphia, PA: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Antibody response ; Cirrhosis ; Donors ; Female ; Grafting ; Hepatitis B - immunology ; Hepatitis B - prevention & control ; Hepatitis B surface antigen ; Hepatitis B Surface Antigens - blood ; Hepatitis B Vaccines - administration & dosage ; Hepatitis B Vaccines - immunology ; Hepatitis B virus ; Hepatitis B virus - immunology ; Humans ; Liver Cirrhosis - immunology ; Liver diseases ; Liver Transplantation ; Male ; Middle Aged ; Prospective Studies ; Risk Factors ; Vaccination ; Vaccines ; Vaccines, Synthetic - administration & dosage ; Vaccines, Synthetic - immunology</subject><ispartof>Liver transplantation, 2000-07, Vol.6 (4), p.440-442</ispartof><rights>2000 American Association for the Study of Liver Diseases</rights><rights>Copyright © 2000 American Association for the Study of Liver Diseases</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4613-34fc2e15fa9a62a7b94b71acd53c5394c09c4ef77fe68c81b2cb99b434d70a133</citedby><cites>FETCH-LOGICAL-c4613-34fc2e15fa9a62a7b94b71acd53c5394c09c4ef77fe68c81b2cb99b434d70a133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1053%2Fjlts.2000.8313$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1053%2Fjlts.2000.8313$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10915165$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Domı́nguez, Mercedes</creatorcontrib><creatorcontrib>Bárcena, Rafael</creatorcontrib><creatorcontrib>Garcı́a, Miguel</creatorcontrib><creatorcontrib>López-Sanroman, Antonio</creatorcontrib><creatorcontrib>Nuño, Javier</creatorcontrib><title>Vaccination Against Hepatitis B Virus in Cirrhotic Patients on Liver Transplant Waiting List</title><title>Liver transplantation</title><addtitle>Liver Transpl</addtitle><description>Patients with cirrhosis may fail to respond to anti–hepatitis B vaccine. An adequate response would be especially interesting when patients are on a liver transplant waiting list. Posttransplantation de novo hepatitis B has been well documented. One possible source is the grafting of organs from hepatitis B surface antigen (HBsAg)–negative, antibody to HBsAg (anti-HBs)–positive, antibody to hepatitis B core antigen–positive donors. The achievement of high titers of anti-HBs could be protective in this setting. We studied prospectively the response rate to recombinant hepatitis B vaccine (3 40-μg doses administered at 0, 1, and 2 months) in 62 patients with end-stage liver disease awaiting liver transplantation. Twenty-two patients showed antibody response (44%). A further 3 doses were administered in 15 of 28 nonresponders and were effective in 9 patients. Thus, the response rate reached 62% (31 of 50 patients completing 1 or 2 vaccination schedules before liver transplantation). Classic hepatitis B vaccination studies of patients with cirrhosis yield lower response rates. Vaccination with this double-dose schedule should be considered in such patients before liver transplantation. (Liver Transpl 2000;6:440-442.)</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibody response</subject><subject>Cirrhosis</subject><subject>Donors</subject><subject>Female</subject><subject>Grafting</subject><subject>Hepatitis B - immunology</subject><subject>Hepatitis B - prevention & control</subject><subject>Hepatitis B surface antigen</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B Vaccines - administration & dosage</subject><subject>Hepatitis B Vaccines - immunology</subject><subject>Hepatitis B virus</subject><subject>Hepatitis B virus - immunology</subject><subject>Humans</subject><subject>Liver Cirrhosis - immunology</subject><subject>Liver diseases</subject><subject>Liver Transplantation</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, Synthetic - administration & dosage</subject><subject>Vaccines, Synthetic - immunology</subject><issn>1527-6465</issn><issn>1527-6473</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1L7DAUhoMofm9dXrKSu5kxp0madqnD9QMGdDHqRghpeqqRTjsmmRH_vRkr4ubqKiHneV8OTwg5AjYGJvnJcxvDOGOMjQsOfIPsgszUKBeKb37dc7lD9kJ4ZgxAlmyb7AArQUIud8nDnbHWdSa6vqOnj8Z1IdJLXKSH6AI9o3fOLwN1HZ0475_66Cy9SUPsYqApMnUr9HTmTRcWrekivTcp2D2mQYgHZKsxbcDDz3Of3J7_m00uR9Pri6vJ6XRkRQ58xEVjMwTZmNLkmVFVKSoFxtaSW8lLYVlpBTZKNZgXtoAqs1VZVoKLWjEDnO-T46F34fuXJYao5y5YbNNC2C-DVpCposhVAv_-CEImVSE5z4qEjgfU-j4Ej41eeDc3_k0D02v1eq1er9XrtfoU-PPZvazmWH_DB9cJUAPw6lp8-6VOT2cy3XMmPqqLIYlJ4sqh18GmH7BYO4826rp3_9vqHSCUo2E</recordid><startdate>200007</startdate><enddate>200007</enddate><creator>Domı́nguez, Mercedes</creator><creator>Bárcena, Rafael</creator><creator>Garcı́a, Miguel</creator><creator>López-Sanroman, Antonio</creator><creator>Nuño, Javier</creator><general>Elsevier Inc</general><general>W.B. Saunders</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200007</creationdate><title>Vaccination Against Hepatitis B Virus in Cirrhotic Patients on Liver Transplant Waiting List</title><author>Domı́nguez, Mercedes ; Bárcena, Rafael ; Garcı́a, Miguel ; López-Sanroman, Antonio ; Nuño, Javier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4613-34fc2e15fa9a62a7b94b71acd53c5394c09c4ef77fe68c81b2cb99b434d70a133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibody response</topic><topic>Cirrhosis</topic><topic>Donors</topic><topic>Female</topic><topic>Grafting</topic><topic>Hepatitis B - immunology</topic><topic>Hepatitis B - prevention & control</topic><topic>Hepatitis B surface antigen</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B Vaccines - administration & dosage</topic><topic>Hepatitis B Vaccines - immunology</topic><topic>Hepatitis B virus</topic><topic>Hepatitis B virus - immunology</topic><topic>Humans</topic><topic>Liver Cirrhosis - immunology</topic><topic>Liver diseases</topic><topic>Liver Transplantation</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, Synthetic - administration & dosage</topic><topic>Vaccines, Synthetic - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Domı́nguez, Mercedes</creatorcontrib><creatorcontrib>Bárcena, Rafael</creatorcontrib><creatorcontrib>Garcı́a, Miguel</creatorcontrib><creatorcontrib>López-Sanroman, Antonio</creatorcontrib><creatorcontrib>Nuño, Javier</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Liver transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Domı́nguez, Mercedes</au><au>Bárcena, Rafael</au><au>Garcı́a, Miguel</au><au>López-Sanroman, Antonio</au><au>Nuño, Javier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccination Against Hepatitis B Virus in Cirrhotic Patients on Liver Transplant Waiting List</atitle><jtitle>Liver transplantation</jtitle><addtitle>Liver Transpl</addtitle><date>2000-07</date><risdate>2000</risdate><volume>6</volume><issue>4</issue><spage>440</spage><epage>442</epage><pages>440-442</pages><issn>1527-6465</issn><eissn>1527-6473</eissn><abstract>Patients with cirrhosis may fail to respond to anti–hepatitis B vaccine. An adequate response would be especially interesting when patients are on a liver transplant waiting list. Posttransplantation de novo hepatitis B has been well documented. One possible source is the grafting of organs from hepatitis B surface antigen (HBsAg)–negative, antibody to HBsAg (anti-HBs)–positive, antibody to hepatitis B core antigen–positive donors. The achievement of high titers of anti-HBs could be protective in this setting. We studied prospectively the response rate to recombinant hepatitis B vaccine (3 40-μg doses administered at 0, 1, and 2 months) in 62 patients with end-stage liver disease awaiting liver transplantation. Twenty-two patients showed antibody response (44%). A further 3 doses were administered in 15 of 28 nonresponders and were effective in 9 patients. Thus, the response rate reached 62% (31 of 50 patients completing 1 or 2 vaccination schedules before liver transplantation). Classic hepatitis B vaccination studies of patients with cirrhosis yield lower response rates. Vaccination with this double-dose schedule should be considered in such patients before liver transplantation. (Liver Transpl 2000;6:440-442.)</abstract><cop>Philadelphia, PA</cop><pub>Elsevier Inc</pub><pmid>10915165</pmid><doi>10.1053/jlts.2000.8313</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1527-6465 |
| ispartof | Liver transplantation, 2000-07, Vol.6 (4), p.440-442 |
| issn | 1527-6465 1527-6473 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71278867 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Antibody response Cirrhosis Donors Female Grafting Hepatitis B - immunology Hepatitis B - prevention & control Hepatitis B surface antigen Hepatitis B Surface Antigens - blood Hepatitis B Vaccines - administration & dosage Hepatitis B Vaccines - immunology Hepatitis B virus Hepatitis B virus - immunology Humans Liver Cirrhosis - immunology Liver diseases Liver Transplantation Male Middle Aged Prospective Studies Risk Factors Vaccination Vaccines Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - immunology |
| title | Vaccination Against Hepatitis B Virus in Cirrhotic Patients on Liver Transplant Waiting List |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T03%3A20%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccination%20Against%20Hepatitis%20B%20Virus%20in%20Cirrhotic%20Patients%20on%20Liver%20Transplant%20Waiting%20List&rft.jtitle=Liver%20transplantation&rft.au=Dom%C4%B1%CC%81nguez,%20Mercedes&rft.date=2000-07&rft.volume=6&rft.issue=4&rft.spage=440&rft.epage=442&rft.pages=440-442&rft.issn=1527-6465&rft.eissn=1527-6473&rft_id=info:doi/10.1053/jlts.2000.8313&rft_dat=%3Cproquest_cross%3E71278867%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1257853328&rft_id=info:pmid/10915165&rft_els_id=S1527646500872238&rfr_iscdi=true |